View live charts, options flow & technicals for Boston Scientific Corporation →
Open Dashboard
Boston Scientific Corporation (BSX) is a healthcare company in the medical devices industry with $21.00B in trailing revenue trading at a 18.2× trailing P/E — analyst consensus: buy.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Key Statistics
Market Cap
$64.66B
Revenue (TTM)
$21.00B
EPS (TTM)
$2.45
EPS (Fwd est.)
$3.42
Employees
59,000
Trailing P/E
18.21
Forward P/E
13.05
PEG Ratio
0.63
Price / Sales
3.08
Price / Book
2.59
EV / EBITDA
13.48
Beta (5Y)
0.57
Analyst Consensus
Consensus
Buy
Analyst Price Target
+36.7% upside
Target: $61.00
Annual Revenue & Net Income
RevenueNet Income
'22
$12.68B
$700.00M
'23
$14.24B
$1.59B
'24
$16.75B
$1.85B
'25
$20.07B
$2.90B
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$0.86
$0.83
Beat (+3.9%)
Apr 2026
$0.80
$0.79
Beat (+1.6%)
Feb 2026
$0.80
$0.78
Beat (+2.4%)
Oct 2025
$0.75
$0.71
Beat (+5.1%)
Next Earnings Report
Boston Scientific Corporation is next expected to report earnings on 28 Oct 2026.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGl…
What is BSX's market cap?
Boston Scientific Corporation has a market capitalization of approximately $64.66B.
What is BSX's P/E ratio?
Boston Scientific Corporation trades at a trailing P/E ratio of 18.2x and a forward P/E of 13.1x, which is below the broad market average of ~25x.
How much revenue does BSX generate?
Boston Scientific Corporation generated $21.00B in trailing 12-month revenue.
What do analysts say about BSX?
The analyst consensus rating for Boston Scientific Corporation is buy, with a mean price target of $61.00. That implies +36.7% upside from the current price.
When does BSX report earnings?
Boston Scientific Corporation is next scheduled to report earnings on 28 Oct 2026.
Does BSX pay a dividend?
Boston Scientific Corporation does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Boston Scientific Corporation on Apsis Markets.